Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

Francesco Oddone; James Kirwan; Fernando Lopez-Lopez; The VISIONARY Study Group; Guna Laganovska

doi:10.1007/s12325-022-02210-5

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

Francesco Oddone (Corresponding Author), James Kirwan, Fernando Lopez-Lopez, The VISIONARY Study Group, Guna Laganovska (Member of the Working Group)

Research output: Contribution to journal › Erratum › peer-review

1 Citation (Scopus)

6 Downloads (Pure)

Abstract

The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

Original language	English
Pages (from-to)	3522-3523
Number of pages	2
Journal	Advances in Therapy
Volume	39
Issue number	8
DOIs	https://doi.org/10.1007/s12325-022-02210-5
Publication status	Published - Aug 2022
Externally published	Yes

Keywords*

Beta-blocker monotherapy
Ocular hypertension
Open-angle glaucoma
Preservative-free topical medication
Prostaglandin analogue monotherapy
Real-world evidence
Tafluprost/timolol fixed-dose combination
VISIONARY study

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1007/s12325-022-02210-5

Correction toFinal published version, 175 KB

Fingerprint

Dive into the research topics of 'Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)'. Together they form a unique fingerprint.

Cite this

Oddone, F., Kirwan, J., Lopez-Lopez, F., The VISIONARY Study Group, & Laganovska, G. (2022). Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). Advances in Therapy, 39(8), 3522-3523. https://doi.org/10.1007/s12325-022-02210-5

Oddone, Francesco ; Kirwan, James ; Lopez-Lopez, Fernando et al. / Correction to : Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). In: Advances in Therapy. 2022 ; Vol. 39, No. 8. pp. 3522-3523.

@article{571b610042844c14924cfc02c2ffae46,

title = "Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)",

abstract = "The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.",

keywords = "Beta-blocker monotherapy, Ocular hypertension, Open-angle glaucoma, Preservative-free topical medication, Prostaglandin analogue monotherapy, Real-world evidence, Tafluprost/timolol fixed-dose combination, VISIONARY study",

author = "Francesco Oddone and James Kirwan and Fernando Lopez-Lopez and Marina Zimina and Claudia Fassari and G{\'a}bor Holl{\'o} and {The VISIONARY Study Group} and Christoph Faschinger and Enping Chen and Gabor Nemeth and Gyorgy Bator and Alexis Tsorbatzoglou and Tamas Acs and Maria Ferencz and Zolt{\'a}n Sohajda and Jeno Toth and Veronika Volner and G{\'a}bor Vogt and Zsolt Biro and Andrea Facsk{\'o} and J{\'a}nos Nemes and Andras Berta and Ilona Elek and Eugene Ng and Gemma Rossi and Luca Rossetti and Michele Vetrugno and Michele Iester and Giorgio Marchini and Vincenzo Scorcia and Giovanni Staurenghi and Carlo Cagini and Tommaso Salgarello and Paolo Bettin and Michele Figus and Scuderi, {Gian Luca} and {De Cilla}, Stefano and Iveta Grundmane and Nora Linavska and Lasma Volksone and Guna Laganovska and Kristine Baumane and Hans Lemij and Gundersen, {Kjell Gunnar} and Valery Erichev and Elmira Adbulaeva and Elena Karlova and Ekaterina Zakharova and Irina Panova and Boris Malyugin",

note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2022.",

year = "2022",

month = aug,

doi = "10.1007/s12325-022-02210-5",

language = "English",

volume = "39",

pages = "3522--3523",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "8",

}

Oddone, F, Kirwan, J, Lopez-Lopez, F, The VISIONARY Study Group & Laganovska, G 2022, 'Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)', Advances in Therapy, vol. 39, no. 8, pp. 3522-3523. https://doi.org/10.1007/s12325-022-02210-5

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). / Oddone, Francesco (Corresponding Author); Kirwan, James; Lopez-Lopez, Fernando et al.
In: Advances in Therapy, Vol. 39, No. 8, 08.2022, p. 3522-3523.

Research output: Contribution to journal › Erratum › peer-review

TY - JOUR

T1 - Correction to

T2 - Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

AU - Oddone, Francesco

AU - Kirwan, James

AU - Lopez-Lopez, Fernando

AU - Zimina, Marina

AU - Fassari, Claudia

AU - Holló, Gábor

AU - The VISIONARY Study Group

A2 - Faschinger, Christoph

A2 - Chen, Enping

A2 - Nemeth, Gabor

A2 - Bator, Gyorgy

A2 - Tsorbatzoglou, Alexis

A2 - Acs, Tamas

A2 - Ferencz, Maria

A2 - Sohajda, Zoltán

A2 - Toth, Jeno

A2 - Volner, Veronika

A2 - Vogt, Gábor

A2 - Biro, Zsolt

A2 - Facskó, Andrea

A2 - Nemes, János

A2 - Berta, Andras

A2 - Elek, Ilona

A2 - Ng, Eugene

A2 - Rossi, Gemma

A2 - Rossetti, Luca

A2 - Vetrugno, Michele

A2 - Iester, Michele

A2 - Marchini, Giorgio

A2 - Scorcia, Vincenzo

A2 - Staurenghi, Giovanni

A2 - Cagini, Carlo

A2 - Salgarello, Tommaso

A2 - Bettin, Paolo

A2 - Figus, Michele

A2 - Scuderi, Gian Luca

A2 - De Cilla, Stefano

A2 - Grundmane, Iveta

A2 - Linavska, Nora

A2 - Volksone, Lasma

A2 - Laganovska, Guna

A2 - Baumane, Kristine

A2 - Lemij, Hans

A2 - Gundersen, Kjell Gunnar

A2 - Erichev, Valery

A2 - Adbulaeva, Elmira

A2 - Karlova, Elena

A2 - Zakharova, Ekaterina

A2 - Panova, Irina

A2 - Malyugin, Boris

PY - 2022/8

Y1 - 2022/8

N2 - The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

AB - The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

KW - Beta-blocker monotherapy

KW - Ocular hypertension

KW - Open-angle glaucoma

KW - Preservative-free topical medication

KW - Prostaglandin analogue monotherapy

KW - Real-world evidence

KW - Tafluprost/timolol fixed-dose combination

KW - VISIONARY study

UR - http://www.scopus.com/inward/record.url?scp=85133655439&partnerID=8YFLogxK

U2 - 10.1007/s12325-022-02210-5

DO - 10.1007/s12325-022-02210-5

M3 - Erratum

C2 - 35731341

AN - SCOPUS:85133655439

SN - 0741-238X

VL - 39

SP - 3522

EP - 3523

JO - Advances in Therapy

JF - Advances in Therapy

IS - 8

ER -

Oddone F, Kirwan J, Lopez-Lopez F, The VISIONARY Study Group, Laganovska G. Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). Advances in Therapy. 2022 Aug;39(8):3522-3523. doi: 10.1007/s12325-022-02210-5